Form D · Pharmaceuticals
Scinai Immunotherapeutics Ltd.
Jerusalem, L3 · CIK 0001611747
Offering snapshot reported Jan 12, 2024 · SEC filing
- Reported sold
- $1.69M Offering amount: $1.69M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 12, 2024 | Initial | $1,694,259 | No comparison | 4 | SEC filing |
| Oct 3, 2023 | Initial | $1,329,254 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $136K
- Finders' fees
- $0
- Form D file number
- 021-502265
This Form D is being filed in connection with the issuance of warrants to purchase up to 5,213,104 American Depositary Shares ("ADSs"), each representing 400 ordinary shares, no par value, of the Company at an exercise price of $0.65 per ADS.
The placement agent (or its designees) also received warrants to purchase up to 156,393 ADSs of the Company at an exercise price of $0.8125 per ADS, each ADS representing 400 ordinary shares, par value NIS 0.01 per share, of the Company.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Jan 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Uri Ben Or | Executive |
| Tamar Ben Yedidia | Executive |
| Mark Germain | Director |
| Jay Green | Director |
| Morris Laster | Director |
| Yael Margolin | Director |
| Elad Mark | Executive |
| Samuel Moed | Director |
| Adi Raviv | Director |
| Amir Reichman | Director, Executive |
| Avner Rotman | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Jerusalem Biopark, 2 Nd Floor, Hadassah Ein Kerem Campus
Jerusalem, L3, 9112001
Jerusalem, L3, 9112001